On July 9, 2025, Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, and Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced a technology and research collaboration to pursue novel drug candidates using Iambic’s leading AI models. Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction.

The collaboration aims to leverage both companies' proprietary data and technologies to explore challenging oncology targets more efficiently than traditional methods. In this multi-year agreement, Iambic will use structures and molecular libraries provided by Revolution Medicines to train bespoke versions of NeuralPLexer, Iambic’s industry-leading model for protein-ligand structure prediction. Revolution Medicines will also have access to Iambic’s PropANE model, a pre-trained graph neural network deployed across dozens of drug properties for lead selection and optimization. Under the terms of the agreement, Iambic is set to receive up to $25 million in upfront and expected near-term performance-based milestone payments.

The Wilson Sonsini team that advised Iambic includes Farah Gerdes, James Clessuras, Adam Kaldor, Colin Bosch, and Matt Bresnahan.

For more information, please see Iambic and Revolution Medicines' news release. Additional coverage can be found on Fierce Biotech.